The embryonic stem cell research question is where Catholic investment screening gets genuinely complex. Unlike abortion or contraception, which have clear moral lines, stem cell research involves technical distinctions that require actual scientific literacy to apply correctly. The USCCB Socially Responsible Investment Guidelines address this, but applying the guidelines to specific pharmaceutical companies requires working through the distinctions carefully.

Let's do that work.

The Catholic moral framework

The foundational teaching is in Donum Vitae (Congregation for the Doctrine of the Faith, 1987) and was expanded in Dignitas Personae (2008). The core principle: human embryos have the moral status of persons from conception, and research that destroys embryos is morally equivalent to killing a person.

The Catechism paragraph 2275 states directly: "One must hold as licit procedures carried out on the human embryo which respect the life and integrity of the embryo and do not involve disproportionate risks for it, but are directed toward its healing, the improvement of its condition of health, or its individual survival. It is immoral to produce human embryos intended for exploitation as disposable biological material."

This creates two distinct moral concerns:

First, embryonic stem cell research itself, which destroys embryos to obtain stem cells, is categorically forbidden.

Second, research that uses cell lines originally derived from aborted fetuses raises a different set of questions about material cooperation with past evil acts.

These two issues get lumped together in popular discussion, but they're actually different problems with different moral analyses.

Embryonic stem cell research directly

Few major pharmaceutical companies engage in direct embryonic stem cell research anymore. The practice peaked in the early 2000s and has largely shifted to induced pluripotent stem cells (iPSCs), which are derived from adult cells and don't require destroying embryos. This shift is partly due to ethical concerns and partly because iPSCs turned out to be scientifically promising.

The companies that historically had significant embryonic stem cell research programs included Geron Corporation (GERN), which had the first FDA-approved embryonic stem cell trial but later discontinued the program. Advanced Cell Technology (later Ocata Therapeutics, acquired by Astellas Pharma) was another. These are relatively small players in the overall market.

Most major pharmaceutical companies, including Pfizer (PFE), Merck (MRK), Novartis (NVS), and Roche (RHHBY), either never had significant embryonic stem cell programs or discontinued them. So the direct embryonic stem cell research concern is a small part of the pharmaceutical exclusion landscape.

Fetal cell lines: the bigger issue

The more widespread concern is the use of fetal cell lines in pharmaceutical research and production. These are cell lines originally derived from aborted fetuses, typically from the 1960s or 1970s, that have been propagated ever since. The most commonly used are HEK-293 (from a 1972 abortion), MRC-5 (from a 1966 abortion), and WI-38 (from a 1962 abortion).

These cell lines are used in drug development, vaccine production, and biological research because they're well-characterized, widely available, and scientifically useful. They're not actively harvested from new abortions. Every cell currently in use is descended from cells taken decades ago.

Does this matter morally? The Catholic Church has addressed this directly.

In 2005, the Pontifical Academy for Life issued a statement on vaccines derived from cells from aborted fetuses. The statement concluded that:

First, the original act of abortion was gravely wrong.

Second, using cell lines derived from those abortions is a form of "very remote mediate material cooperation" with the original act.

Third, in the absence of ethical alternatives, Catholics may licitly use vaccines and medications produced using such cell lines.

Fourth, Catholics have a "grave responsibility" to push for the development of ethical alternatives and to avoid supporting the continuation of these practices where possible.

The Congregation for the Doctrine of the Faith reaffirmed this analysis in 2020 in the context of COVID-19 vaccines, saying Catholics may licitly receive vaccines that used fetal cell lines in development when no alternative is available.

Applying this to investing

Here's where it gets complicated. Using a vaccine to save your life is different from owning stock in the company that makes it. The moral analyses aren't identical because the situations are different.

The USCCB guidelines address this by distinguishing between:

Companies that actively destroy embryos or harvest tissue from abortions. These are categorically excluded. Any meaningful connection triggers the screening.

Companies that use historical fetal cell lines in research without active embryo destruction. These require prudential judgment about the level of cooperation and the alternatives available.

Companies whose products are tested using fetal cell lines but don't contain fetal cells or require ongoing embryo destruction. These are the most remote case.

Most Catholic fund managers apply the exclusion broadly in the first category and more narrowly in the second and third. The logic: owning stock in a company that needs ongoing embryo destruction is proximate material cooperation. Owning stock in a company that uses historical cell lines is more remote, potentially permissible with prudential judgment.

The big pharma cases

Pfizer (PFE) has used fetal cell lines in research for various products, including some of its vaccines. The company didn't use fetal cell lines in the manufacture of its COVID-19 vaccine (that was done with BioNTech), but historical cell lines were used in lab testing of the vaccine. Pfizer also has other products with varying connections.

Moderna (MRNA) similarly used HEK-293 cells in testing its COVID-19 vaccine, though the vaccine itself doesn't contain fetal cells. This created ongoing debate in Catholic circles about whether Moderna should be excluded.

Johnson & Johnson (JNJ) had a more direct issue: its COVID-19 vaccine was manufactured using PER.C6 cells, a fetal cell line derived from an abortion in 1985. The CDF's 2020 guidance acknowledged this and still concluded the vaccine could be morally used when no alternative was available, but the Pfizer and Moderna vaccines were preferable.

Merck (MRK) has fetal cell lines in some products, most notably the MMR vaccine (measles, mumps, rubella), which uses WI-38 and MRC-5 cell lines. This has been a source of concern for Catholic parents for decades.

The question for investors: does this trigger exclusion?

Ave Maria Mutual Funds (AVMNX) excludes all of these names, though primarily for other reasons (contraception, abortifacients, etc.). Knights of Columbus Asset Management takes a more nuanced approach. Catholic Responsible Investments funds apply detailed research before including or excluding.

The answer isn't mechanical. It depends on which moral analysis you find most compelling and how strict you want your screening to be.

Clean healthcare alternatives

If you want healthcare exposure without the fetal cell line concerns, here are some options:

Thermo Fisher Scientific (TMO) provides lab equipment and diagnostics. It doesn't produce vaccines or drugs directly, so its connection to fetal cell lines is more remote.

Intuitive Surgical (ISRG) makes robotic surgery systems. Hardware manufacturers don't have the same research dependencies.

Edwards Lifesciences (EW) focuses on heart valves and cardiac surgery products.

Stryker (SYK) makes medical devices for orthopedic and surgical applications.

Regeneron (REGN) has a cleaner profile than the big pharma giants, though any biotech needs individual screening.

Vertex Pharmaceuticals (VRTX) focuses on cystic fibrosis treatments with a relatively clean profile.

Waters Corporation (WAT) makes analytical instruments for pharmaceutical research.

Dexcom (DXCM) focuses on continuous glucose monitoring for diabetes patients.

These aren't perfect substitutes for the market cap and dividend profile of JNJ or PFE, but they provide healthcare exposure without the most concerning moral conflicts.

The research frontier

It's worth noting that the pharmaceutical industry is actively moving away from fetal cell line dependence, partly for ethical reasons and partly for technical ones. Induced pluripotent stem cells (iPSCs) and adult stem cells offer alternatives that don't require embryo destruction. Some companies are specifically focused on ethical alternatives.

Dignitas Personae paragraph 32 endorses this direction: "Adult stem cells, however, do not present the ethical problems connected with the use of embryos, and should be favored in scientific research."

Catholic investors can actually reward companies moving in this direction. This is the "do good" pillar of the USCCB guidelines in action: active positive investment in companies pursuing ethical research, not just avoidance of companies doing unethical research.

What you can actually do

First, recognize that the fetal cell line issue is genuinely complex and doesn't have a clean mechanical answer. Anyone who tells you they can screen it perfectly is oversimplifying.

Second, understand that the USCCB guidelines give you a framework for prudential judgment, not a compliance checklist. Different faithful Catholic investors reach different conclusions about specific companies.

Third, consider engagement alongside divestment. Shareholder resolutions pushing pharmaceutical companies toward ethical alternatives have actually influenced corporate behavior over the past decade.

Fourth, support research into alternatives. Companies developing iPSC technologies and adult stem cell therapies deserve positive investment under Catholic social teaching, not just avoidance.

Fifth, recognize that personal use and investment are different moral questions. Receiving a vaccine that used fetal cell lines in development is permitted by Church teaching when no alternative exists. Owning stock in the manufacturer is a separate analysis.

The weight of the question

The embryonic stem cell research and fetal cell line questions are weighty because they sit at the intersection of medical progress and moral absolutes. The Church doesn't oppose medical research. It opposes specific methods that treat human life as disposable material.

John Paul II's Evangelium Vitae (1995) paragraph 63 addresses this directly: "The use of human embryos or fetuses as an object of experimentation constitutes a crime against their dignity as human beings who have a right to the same respect owed to a child once born, just as to every person."

Investing in companies that violate that dignity, even at one remove, is morally weighty. The USCCB guidelines treat it that way. Whether your own prudential judgment leads you to exclude specific companies or engage with them, the moral seriousness of the question deserves serious attention.

Your portfolio is a set of relationships with companies and their practices. Making those relationships conscious is what Catholic investing is ultimately about.

Embryonic Stem Cell Research: Pfizer, Merck, and the Fetal Cell Line Issue